Johnson & Johnson (JNJ) announced positive topline results from the pivotal late-stage MDD3001 study, which evaluated its investigational oral drug seltorexant in patients with major depressive disorder (MDD) with insomnia symptoms.The MDD3001 study evaluated the drug as an adjunctive treatment to baseline antidepressants in adult and elderly patients who did not benefit from antidepressants alone. The study met all its primary and secondary endpoints.Treatment with seltorexant achieved statistically signif ...